Order Breast
Cancer
IndexOrder Breast Cancer IndexOrder Breast Cancer Index
BCI CLINICAL EVIDENCE

The Predictive Power Of Breast Cancer Index

Breast Cancer Index Has Demonstrated Consistent Predictive Evidence Across 5 Studies and Over 4,500 Patients

Data supports comprehensive utility in pre- and post-menopausal women with various treatment histories and clinical features.

BCI CLINICAL EVIDENCE

Results from the Recent IDEAL Study

Results from the Recent IDEAL Study

The largest Breast Cancer Index validation expands on previous evidence, establishing the biomarker as being agnostic to TAM or AI treatment in women with HR+, early-stage breast cancer.

BCI CLINICAL EVIDENCE

BCI Predictive Validation: Trans-aTTom

Results from the Trans-aTTom Study

Trans-aTTom was the second prospective-retrospective study validating Breast Cancer Index prediction and established level 1B evidence for BCI as a biomarker for extended endocrine therapy response.

BCI CLINICAL EVIDENCE

Breast Cancer Index Prognostic Validation For Risk Of Late Distant Recurrence

Breast Cancer Index Has Extensive Validation Demonstrating Its Ability To Determine Risk Of Late (Post 5-Year) Distant Recurrence

The ability of Breast Cancer Index to determine an individual’s late distant recurrence has been validated across multiple studies, including various treatment histories, and a mix of pre- and post-menopausal patients.

OB/GYN RESOURCES

An OB/GYN's Perspective on BCI

OB/GYN's familiarity with adverse events from endocrine therapy gives patients an outlet

Watch Alison Cowan, MD, talk about the pivotal role OB/GYNs play in navigating treatment.

CLINICAL LANDSCAPE

Prognostic ≠ Predictive

BCI Is THE ONLY Commercially Available Test That Can Predict Whether Another 5 Years Of Endocrine Therapy Is Likely To Help Reduce Her Risk Of Late-Distant Recurrence

While clinicopathologic factors may help in the prognostic evaluation of recurrence risk, these factors and other commercially available tests have not been validated to predict benefit from extended endocrine therapy.

CLINICAL INSIGHTS

Breast Cancer Index

Predictive And Prognostic Information For Extended Endocrine Therapy Decision-Making

Breast Cancer Index (BCI) is THE ONLY commercially available test validated to inform the decision regarding extended endocrine therapy based on...

CLINICAL INSIGHTS

Ten Years Of Endocrine Therapy: Is It Right For Your Patients?

Nearly 95% Of Women With Early-Stage, Hormone Receptor–Positive (HR+) Breast Cancer Do Not Benefit From Extended Endocrine Therapy

Trials consistently demonstrate that only 3-5% of women benefit from extended endocrine therapy, supporting the strong need for individualized patient selection rather than broad use of prolonged treatment.

SIDE EFFECTS

Side Effects And Impact On Patient Quality Of Life Drives Noncompliance

In The Extended Endocrine Setting, Nearly 40% Of Patients Fail To Take Their Medication As Prescribed

In a Breast Cancer Index decision impact study, after receiving their results, 82% of patients that were recommended extended endocrine therapy reported they were more likely to be compliant with their treatment plan.

BCI CLINICAL EVIDENCE

Breast Cancer Index (BCI) Is Changing Physician Behavior

BCI results changed physician treatment recommendations in 30% of patients

In a prospective decision-impact study led by Yale University of 141 patients with early-stage, HR+ breast cancer on endocrine therapy for over 3.5 years, 30% of physician treatment recommendations regarding extended therapy changed after receiving a BCI result.

BCI CLINICAL EVIDENCE

Breast Cancer Index Is Transforming Clinical Assumptions

Looking Beyond Clinical Features Based On Individual Tumor Biology Can Impact Clinical Decision-Making

In a clinical study of 547 patients considered to be clinically low risk (T1N0), Breast Cancer Index identified ~25% as likely to benefit from extended endocrine therapy and high risk of late distant recurrence.

News & Insights

April 25, 2022

ASCO® Clinical Practice Guideline Now Includes Breast Cancer Index® to Guide Decisions about Extended Endocrine Therapy

Hologic, Inc. announced today that the ASCO® Clinical Practice Guideline has published an update which expands the utility of Breast Cancer Index® (BCI) within its Clinical Practice Guideline: “Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer.”

Read more
December 17, 2020

Breast Cancer Index® demonstrates its ability to predict preferential endocrine benefit irrespective of risk for HR+ early-stage breast cancer patients

Evidence demonstrating the ability of Breast Cancer Index to predict preferential endocrine benefit irrespective of clinical risk for HR+ early-stage breast cancer patients was highlighted during a Spotlight session on December 9th at this years’ San Antonio Breast Cancer...

Read more
December 08, 2020

Biotheranostics to premiere new data on Breast Cancer Index® and prediction of endocrine therapy benefit at SABCS 2020

New data on Biotheranostics’ Breast Cancer Index test will be highlighted at the 43rd annual San Antonio Breast Cancer Symposium (SABCS) being held virtually from December 8-12, 2020. Breast Cancer Index continues to expand on a strong body of evidence as the only commercially ...

Read more
October 29, 2020

Biotheranostics' Breast Cancer Index® IDEAL study expands clinical evidence for prediction of extended endocrine benefit to patients treated with aromatase inhibitors.

Biotheranostics announces the publication of results from the IDEAL study in Clinical Cancer Research which reports novel findings of the Breast Cancer Index (BCI) and predictive evidence in patients treated with aromatase inhibitors. In collaboration with Leiden University...

Read more

Not Another Minute Prescribing Treatment That May Not Benefit Her

It is important to determine whether the treatment is likely to reduce her risk of recurrence before exposing her to potential risks associated with extended treatment. In the ATLAS Trial2 (extended TAM) 16 recurrences were prevented...

Read more

References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.2.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed February 10, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. The NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 2. Andre F et al. J Clin Oncol. Published online April 19, 2022. DOI: 10.1200/JCO.22.00069​. Referenced with permission from the American Society of Clinical Oncology (ASCO®) Clinical Practice Guideline Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer. © American Society of Clinical Oncology. 2024. All rights reserved. To view the most recent and complete version of the guideline, go online to https://ascopubs.org/jco/special/guidelines [ascopubs.org].  ASCO makes no warranties of any kind whatsoever regarding their content, use of application and disclaims any responsibility for their application or use in any way. 3. Davies C, et al. Lancet. 2013;381:805-816. 4. Gray R, et al. J Clin Oncol. 2013;31:(suppl; abstr 5). 5. Jakesz R, et al. J Natl Cancer Inst. 2007;99:1845-1853. 6. Goss PE, et al. J Natl Cancer Inst. 2005;97:1262-1271. 7. Mamounas EP, et al. NSABP B-42. GS4-01. SABCS 2019. 8. Goss PE, et al. N Engl J Med. 2016;375:209-219.

Back to Top